In California, Invitrogen Corp. of Carlsbad will partner with Emiliem Inc. of Emeryville to screen the latter’s cancer-targeting multiple kinase inhibitors. Under terms of the agreement, Invitrogen will use its SelectScreen kinase profiling system to confirm the potency and specificity of compounds created using Emiliem’s K-Star technology. In the second phase of investigations, the former company will analyze with its cellular profiling system how the compounds influence biological pathways. Through cytochrome P450 screening, the company will assess the inhibitory effects of the molecules on drug-metabolizing liver enzymes as well.